Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY

(BMY)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Stada, Angelini among final bidders for $1 billion Bristol-Myers' UPSA unit - sources

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/08/2018 | 02:42pm EDT
FILE PHOTO: The logo of Stada Arzneimittel AG is pictured at their headquarters in Bad Vilbel near Frankfurt

FRANKFURT/LONDON (Reuters) - German drugmaker Stada and Italian healthcare company Angelini are the only industry players to be shortlisted to make final bids for Bristol-Myers Squibb's French over-the-counter drugs business, four sources close to the deal said.

Two private equity firms, CVC Capital Partners and PAI Partners, have also made it through to the final round of the auction for UPSA, the maker of Dafalgan and Efferalgan painkillers, the sources told Reuters.

The sale, which is handled by Jefferies and Deutsche Bank, is worth about 1 billion euros (839.95 million pounds).

Bristol-Myers Squibb (BMS), Stada, CVC and PAI declined to comment while Angelini was not immediately available for comment.

BMS has given bidders a deadline of late November to submit final proposals, the sources said.

The U.S. firm took full control of the unit, which also produces effervescent aspirin and vitamin C, 24 years ago.

It is now looking to concentrate on high-margin prescription drugs, particularly for cancer, and hopes to sell UPSA for a multiple of 7.5 to 8 times its core earnings of 120 million-130 million euros, the sources said.

Germany's Stada, which is backed by private equity firms Bain Capital and Cinven, is widely seen as the frontrunner for the deal as it seeks to build scale through major acquisitions, the sources said.

Italy's Angelini, which is advised by BNP Paribas, is also willing to embark on a big deal, two of the sources said.

The sale initially drew interest from other big industry players including U.S.-run drugmaker Mylan NV and Japanese healthcare firm Taisho Pharmaceutical which subsequently walked away from the process, the sources said.

UPSA generated revenue of 425 million euros in 2017 and employs about 1,500 people in France.

The sale comes amid a series of high-profile deals in the consumer health industry including Procter & Gamble's acquisition of Merck KGaA's vitamin brands in April and GlaxoSmithKline deal to buy Novartis out of their consumer healthcare joint venture for $13 billion.

(Reporting by Arno Schuetze in Frankfurt and Pamela Barbaglia in London; Additional reporting by Stephen Jewkes in Milan and Matthias Blamont in Paris; Editing by Edmund Blair)

By Arno Schuetze and Pamela Barbaglia

Stocks mentioned in the article
ChangeLast1st jan.
BRISTOL-MYERS SQUIBB COMPANY -1.55% 48.16 Delayed Quote.-7.35%
GLAXOSMITHKLINE -0.70% 1555 Delayed Quote.4.28%
MYLAN NV -1.91% 28.69 Delayed Quote.4.71%
NOVARTIS -0.13% 93.04 Delayed Quote.10.71%
PROCTER & GAMBLE COMPANY -0.81% 101.66 Delayed Quote.10.60%
STADA ARZNEIMITTEL 0.00%End-of-day quote.-8.87%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BRISTOL-MYERS SQUIBB COMPA
03/22BRISTOL MYERS SQUIBB : Additional Proxy Soliciting Materials - Non-Management (d..
PU
03/20BRISTOL MYERS SQUIBB : Overheard
DJ
03/19BRISTOL MYERS SQUIBB : Correction to Bristol-Myers Squibb Overheard Article
DJ
03/19If This Is Failure, Show Me Success -- Overheard
DJ
03/19BRISTOL MYERS SQUIBB : Starboard Issues Investor Presentation Opposing Bristol-M..
PR
03/19BRISTOL MYERS SQUIBB : Files Investor Presentation Highlighting Significant Bene..
BU
03/18BRISTOL MYERS SQUIBB : Additional Proxy Soliciting Materials - Non-Management (d..
PU
03/18BRISTOL MYERS SQUIBB : Filing of certain prospectuses and communications in conn..
PU
03/15BRISTOL MYERS SQUIBB : Proxy Statment - Contested Solicitations (definitive)
PU
03/15BRISTOL MYERS SQUIBB : Mutual funds start to put their mouth where their money i..
RE
More news
Financials ($)
Sales 2019 23 977 M
EBIT 2019 6 881 M
Net income 2019 6 782 M
Finance 2019 3 655 M
Yield 2019 3,41%
P/E ratio 2019 11,89
P/E ratio 2020 11,52
EV / Sales 2019 3,13x
EV / Sales 2020 2,85x
Capitalization 78 630 M
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 57,0 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Johanna Mercier President & Head-US Commercial
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-7.35%78 630
JOHNSON & JOHNSON6.09%364 560
NOVARTIS10.71%239 248
ROCHE HOLDING LTD.10.68%233 745
PFIZER-4.12%232 343
MERCK AND COMPANY7.70%212 409